Lung Sarcomatoid Carcinoma
NCI Definition: A rare, aggressive, poorly differentiated, non-small cell lung carcinoma characterized by the presence of a sarcomatoid component often associated with giant cell differentiation. There is a male to female ratio of 4:1. Clinical symptoms include cough, hemoptysis, chest pain, progressive dyspnea and fever secondary to recurrent pneumonia. Cigarette smoking is a major risk factor. 
Lung sarcomatoid carcinomas most frequently harbor alterations in TP53, KRAS, MET, CDKN2A, and NF1 .
TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, KRAS Mutation, and KRAS Exon 2 Mutation are the most common alterations in lung sarcomatoid carcinoma .
There are 2 clinical trials for lung sarcomatoid carcinoma, of which 2 are open and 0 are completed or closed. Of the trials that contain lung sarcomatoid carcinoma as an inclusion criterion, 2 are phase 2 (2 open).
Ipilimumab, nilotinib, and nivolumab are the most common interventions in lung sarcomatoid carcinoma clinical trials.
Significant Genes in Lung Sarcomatoid Carcinoma
CD274 is an inclusion eligibility criterion in 1 clinical trial for lung sarcomatoid carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and lung sarcomatoid carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.